Article
A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes.
Nature communications - 11 May 2021
Guo Yu, Huang Lisu, Zhang Guangshun, Yao Yanfeng, Zhou He, Shen Shu, Shen Bingqing, Li Bo, Li Xin, Zhang Qian, Chen Mingjie, Chen Da, Wu Jia, Fu Dan, Zeng Xinxin, Feng Mingfang, Pi Chunjiang, Wang Yuan, Zhou Xingdong, Lu Minmin, Li Yarong, Fang Yaohui, Lu Yun-Yueh, Hu Xue, Wang Shanshan, Zhang Wanju, Gao Ge, Adrian Francisco, Wang Qisheng, Yu Feng, Peng Yun, Gabibov Alexander G, Min Juan, Wang Yuhui, Huang Heyu, Stepanov Alexey, Zhang Wei, Cai Yan, Liu Junwei, Yuan Zhiming, Zhang Chen, Lou Zhiyong, Deng Fei, Zhang Hongkai, Shan Chao, Schweizer Liang, Sun Kun, Rao Zihe
Abstract excerpt
COVID-19 pandemic caused by SARS-CoV-2 constitutes a global public health crisis with enormous economic consequences. Monoclonal antibodies against SARS-CoV-2 can provide an important treatment option to fight COVID-19, especially for the most vulnerable populations. In this work, potent antibodies binding to SARS-CoV-2 Spike protein were identified from COVID-19 convalescent patients. Among them, P4A1 interacts...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.